Millions of people around the world are living with a genetically defined disease. Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases. For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.
Cogent Biosciences is building a world-class discovery organization in Boulder, CO focused on pioneering best-in-class, small molecule therapeutics to improve upon existing drugs with clear limitations and safety concerns, with the goal of creating new breakthroughs for diseases where others have been unable to find solutions.
Cogent is driven by the patients we serve and committed to the opportunity to deliver novel precision therapies to patients with unmet medical needs. We are a Company of people who are passionate and dedicated to turning the promises of our therapies into reality in order to transform the lives of patients.
Today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.
today announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with...
Today announced a poster presentation at the European Hematology Association (EHA) Congress being held June 9-12, 2022.
Today announced financial results for the fourth quarter and year ended December 31, 2021...